TY - JOUR
T1 - TERT promotor status does not add prognostic information in IDH-wildtype glioblastomas fulfilling other diagnostic WHO criteria
T2 - A report of the RANO resect group
AU - Karschnia, Philipp
AU - Young, Jacob S.
AU - Dono, Antonio
AU - Häni, Levin
AU - Juenger, Stephanie T.
AU - Sciortino, Tommaso
AU - Bruno, Francesco
AU - Teske, Nico
AU - Morshed, Ramin A.
AU - Haddad, Alexander F.
AU - Zhang, Yalan
AU - Stoecklein, Sophia
AU - Vogelbaum, Michael A.
AU - Beck, Juergen
AU - Tandon, Nitin
AU - Hervey-Jumper, Shawn
AU - Molinaro, Annette M.
AU - Rudà, Roberta
AU - Bello, Lorenzo
AU - Schnell, Oliver
AU - Esquenazi, Yoshua
AU - Ruge, Maximilian I.
AU - Grau, Stefan J.
AU - Van Den Bent, Martin
AU - Weller, Michael
AU - Berger, Mitchel S.
AU - Chang, Susan M.
AU - Tonn, Joerg Christian
N1 - Publisher Copyright:
© Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology 2022.
PY - 2022/1
Y1 - 2022/1
N2 - In IDH-wildtype glioblastomas which meet the histopathological or molecular diagnosis criteria, it remains unclear whether the presence of TERT promotor mutations provides additional prognostic information. Based on a multicenter cohort of 466 IDH-wildtype glioblastomas (including 396 with and 70 patients without TERT promotor mutations), we found that TERT promotor mutations were neither associated with progression-free survival nor overall survival. This held true in various treatment-based or molecular subgroups. This argues against standardized analysis for TERT promotor mutation status for the purpose of prognostic or therapeutic relevance in newly diagnosed IDH-wildtype glioblastoma that otherwise meets the histopathological and molecular diagnosis criteria.
AB - In IDH-wildtype glioblastomas which meet the histopathological or molecular diagnosis criteria, it remains unclear whether the presence of TERT promotor mutations provides additional prognostic information. Based on a multicenter cohort of 466 IDH-wildtype glioblastomas (including 396 with and 70 patients without TERT promotor mutations), we found that TERT promotor mutations were neither associated with progression-free survival nor overall survival. This held true in various treatment-based or molecular subgroups. This argues against standardized analysis for TERT promotor mutation status for the purpose of prognostic or therapeutic relevance in newly diagnosed IDH-wildtype glioblastoma that otherwise meets the histopathological and molecular diagnosis criteria.
UR - https://www.scopus.com/pages/publications/85145459696
U2 - 10.1093/noajnl/vdac158
DO - 10.1093/noajnl/vdac158
M3 - Article
AN - SCOPUS:85145459696
SN - 2632-2498
VL - 4
JO - Neuro-Oncology Advances
JF - Neuro-Oncology Advances
IS - 1
M1 - vdac158
ER -